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Abstract
Hepatocellular accumulation of bile acids due to inhibition of the canalicular bile salt export pump
(BSEP/ABCB11) is one proposed mechanism of drug-induced liver injury (DILI). Some
hepatotoxic compounds also are potent inhibitors of bile acid uptake by Na+-dependent
taurocholate cotransporting polypeptide (NTCP/SLC10A1). This study used a cassette dosing
approach in rat and human sandwich-cultured hepatocytes (SCH) to determine whether known or
suspected hepatotoxic drugs inhibit bile acid transport individually or in combination. [3H]-
Taurocholate served as the NTCP/BSEP probe substrate. Individually, cyclosporin A and rifampin
decreased taurocholate in vitro biliary clearance (Clbiliary) and biliary excretion index (BEI) by
more than 20% in rat SCH, suggesting that these drugs primarily inhibited canalicular efflux. In
contrast, ampicillin, carbenicillin, cloxacillin, nafcillin, oxacillin, carbamazepine, pioglitazone,
and troglitazone decreased the in vitro Clbiliary by more than 20% with no notable change in BEI,
suggesting that these drugs primarily inhibited taurocholate uptake. Cassette dosing (n=2–4
compounds per cassette) in rat SCH yielded similar findings, and results in human SCH were
consistent with rat SCH. In summary, cassette dosing in SCH is a useful in vitro approach to
identify compounds that inhibit the hepatic uptake and/or excretion of bile acids, which may cause
DILI.
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INTRODUCTION
Drug-induced liver injury (DILI), a clinical problem worldwide (reviewed in Lucena et al.,
2008; Norris et al., 2008), is a leading reason for withdrawal of approved drugs from clinical
use or mandated usage restrictions on drug labels, and frequently contributes to attrition of
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drug candidates during development (Bakke et al., 1995; Kaplowitz, 2005; Kola and Landis,
2004). Numerous pathophysiological mechanisms underlie hepatotoxicity but remain poorly
understood, and many cases of DILI are categorized as idiosyncratic (i.e., rare hepatotoxic
reactions of unknown etiology). In addition, DILI is difficult to predict with existing animal
models and only approximately half of the drugs that cause human hepatotoxicity can be
identified during preclinical testing in rodents, dogs, and monkeys (Olson et al., 2000).
Cholestasis is marked by the accumulation of bile acids and bile constituents within
hepatocytes; toxicity ensues due, in part, to the detergent-like effects of bile acids, which
cause cellular apoptosis or necrosis and mitochondrial dysfunction (reviewed in Sokol et al.,
2006). Many drugs and/or metabolites inhibit transport proteins responsible for the
hepatobiliary transport of bile acids (reviewed in Kosters and Karpen, 2008; Pauli-Magnus
and Meier, 2006). In addition, genetic and environmental factors that modulate the
expression and/or activity of these transport proteins have been linked directly to cholestasis
or to an increased susceptibility to its development (reviewed in Kosters and Karpen, 2008;
Pauli-Magnus and Meier, 2006; Trauner and Boyer, 2003).
Transport proteins are increasingly recognized as pivotal in determining the
pharmacokinetics and the pharmacological or toxicological effects of a number of drugs
(Hirano et al, 2006; Szakács et al., 2008). Numerous transport proteins are responsible for
the movement of bile acids into and out of hepatocytes (reviewed in Kosters and Karpen,
2008; Trauner and Boyer, 2003; Zollner et al., 2006). The sodium-taurocholate
cotransporting polypeptide (NTCP/Ntcp; SLC10A1) and the bile salt export pump (BSEP/
Bsep; ABCB11) are the predominant proteins involved in bile acid transport and homeostasis
in humans and rats. On the basolateral/sinusoidal membrane of hepatocytes, NTCP/Ntcp
mediates the uptake of taurine- and glycine-conjugated (i.e., taurocholate) and unconjugated
bile acids from the blood in a sodium-dependent manner. Organic anion-transporting
polypeptides (OATPs/Oatps; SLCOs) transport predominantly unconjugated bile acids in a
sodium-independent manner. Multidrug resistance-associated proteins (MRP/Mrp) 3
(ABCC3) and 4 (ABCC4), and organic solute transporter (OST) α/β efflux bile acids from
hepatocytes back into the blood. On the canalicular/apical membrane, BSEP/Bsep effluxes
taurine- and glycine-conjugated bile acids into bile canaliculi, serving as a driving force for
bile salt-dependent bile flow and for the concentration of bile acids in bile; MRP2/Mrp2
effluxes glucuronidated and sulfated bile acids.
Several in vitro models exist for assessing compound toxicity due to inhibition of transport
proteins. Human and rat sandwich-cultured hepatocytes (SCH) are physiologically relevant
in vitro models that maintain many in vivo structural and functional characteristics,
including canalicular and basolateral membrane domains, expression and localization of
liver-specific proteins, and functional bile excretion into sealed canalicular networks
(LeCluyse et al., 1994, 2000; Liu et al., 1998, 1999a,b). These models have been used
previously to study the inhibitory effects of drugs (e.g., troglitazone, nefazadone,
antiretroviral compounds) on bile acid uptake and biliary excretion (Kemp et al., 2005;
Kostrubsky et al., 2006; Marion et al., 2007; McRae et al., 2006).
Because of increased attention to DILI (EMEA, 2008; FDA, 2007), a robust assay utilizing
SCH for inhibition of bile acid transport would be beneficial during drug development,
allowing early identification of drug candidates that may cause cholestasis in humans.
Traditionally, compounds are administered individually in preclinical drug development
studies, a time-consuming, labor-intensive, and cost-ineffective practice. Cassette dosing, or
the simultaneous administration of multiple compounds, was developed as an alternative
screening method. This strategy has been used widely in vitro and in vivo to study the
pharmacokinetics and metabolism of drug candidates (reviewed in White and Manitpisitkul,
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2001; Zhou et al., 2004). To our knowledge, there are no reports in the literature regarding
the use of cassette dosing to identify inhibitors of hepatic bile acid transport. The purpose of
the present study was two-fold. First, inhibition of bile acid (taurocholate) transport by
hepatotoxic drugs was assessed in rat and human SCH to determine whether it was a
common mechanism of hepatotoxicity. Second, the feasibility of using a cassette dosing




Fetal bovine serum (FBS), dexamethasone (Dex), Hanks’ balanced salts solution (HBSS)
supplemented with (H-1387) or without (H-4891) calcium chloride, phenytoin, minocycline,
azlocillin, nafcillin, ticarcillin, cloxacillin, carbenicillin, oxacillin, ampicillin, amoxicillin,
haloperidol, chlorpromazine, valproic acid, pentamidine, prednisone, ibuprofen, etoposide,
ceftriaxone, cefuroxime, carbamazepine, indomethacin, clotrimazole, bezafibrate,
bifonazole, colchicine, hydralazine, menadione, piroxicam, isoniazid, sodium taurocholate,
methanol, and Triton X-100 were obtained from Sigma-Aldrich (St. Louis, MO). Rifampin
was obtained from Spectrum Chemical and Laboratory Products, Inc. (Gardena, CA).
Troglitazone was obtained from Cayman Chemical (Ann Arbor, MI). Tienilic acid was
purchased from BD Gentest (Woburn, MA). Pioglitazone was purchased from ChemPacific
Corporation (Baltimore, MD). Cyclosporin A was obtained from Calbiochem (La Jolla,
CA). GlaxoSmithKline, Inc. Chemical Registry supplied cefalexin. Collagenase (type 1,
class 1) was purchased from Worthington Biochemicals (Lakewood, NJ). ITS+™ (insulin/
transferrin/selenium) culture supplement, BioCoat™ collagen I plates, and Matrigel™
basement membrane matrix were purchased from BD Biosciences Discovery Labware
(Bedford, MA). Dulbecco’s modified Eagle’s medium (DMEM) without phenol red,
minimal essential medium (MEM) nonessential amino acids solution (100x), penicillin G-
streptomycin solution, insulin, and L-glutamine were obtained from Invitrogen (Carlsbad,
CA). [3H]-Taurocholate (5 Ci/mmol, >97% purity) was purchased from PerkinElmer Life
and Analytical Sciences (Boston, MA). Bio-Safe II™ liquid scintillation cocktail was
obtained from Research Products International (Mt. Prospect, IL). Bicinchoninic acid (BCA)
protein assay reagents and bovine serum albumin for the protein assay standard were
purchased from Pierce Chemical Co. (Rockford, IL). Absolute ethanol (USP) was purchased
from Aaper Alcohol and Chemical Co., Inc. (Shelbyville, KY). Dimethyl sulfoxide and
chloroform were obtained from Fisher Scientific Co. (Pittsburgh, PA). The Cytotoxicity
Detection Kit (LDH [Lactate Dehydrogenase]) was purchased from Roche Applied Science
(Indianapolis, IN). All other chemicals and reagents were of analytical grade and available
from commercial sources.
Animals
Male Wistar rats (200–300 g) from Charles River Laboratories, Inc. (Raleigh, NC) were
used as liver donors for hepatocyte isolation. Animals were allowed to acclimate for at least
five days prior to surgery. Rats were maintained in a controlled environment with a 12-h
light/dark cycle and allowed free access to food and water. All animal procedures were
approved by the Institutional Animal Care and Use Committee of The University of North
Carolina at Chapel Hill (UNC).
Isolation and Culture of Primary Rat and Human Hepatocytes
Rat (Wolf et al., 2008) and human (Ghibellini et al., 2007) SCH were prepared and
maintained as described previously. Human tissue was obtained from liver resections
performed by qualified medical staff in the Department of Surgery at the UNC School of
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Medicine; hepatocytes were isolated from normal tissue surrounding the tumor that would
have otherwise been discarded. Donor consent and approval of the UNC Biomedical
Investigational Review Board was acquired prior to the surgery. Information on the liver
donors is provided in Supplementary Table 1. Canalicular network development in rat and
human SCH was monitored daily by phase contrast microscopy, as described previously
(Ghibellini et al., 2007), and experiments were performed when canalicular network
formation was optimal (day 4 for rat and either day 9 or 10 for human SCH).
Selection of Compounds and Test Concentrations
The compounds for this study were selected based on literature reports indicating that they
were hepatotoxic or that they increased liver enzymes in the plasma/serum of rats and/or
humans, as presented in Supplementary Table 2. Some hepatotoxic events associated with
selected compounds were idiosyncratic and rare, while others were more common. The
expected maximal therapeutic blood concentration and unbound fraction of each drug in
humans was obtained from the literature (Lacy et al., 2002; Micromedex® Healthcare
Series, Thomson Corporation, Stamford, CT; Thummel and Shen, 2001). The unbound
concentration of each drug in the blood was determined as the product of the total
concentration and the unbound fraction. Drug concentrations selected for this study were
approximately 10 times the expected therapeutic unbound drug concentration in the blood.
Selected compounds were tested in both rat and human SCH to determine the suitability of
rat SCH in screening for bile acid transport inhibition in humans.
Transport Studies
Bile acid transport was investigated in SCH as described previously by Kemp et al. (2005),
with modifications. Briefly, hepatocytes were rinsed twice with 2 ml warm HBSS
containing Ca2+ (standard buffer) to maintain tight junction integrity and sealed bile
canalicular networks, or with Ca2+-free HBSS to disrupt tight junctions and open bile
canalicular networks (Figure 1). Subsequently, incubation of cells was continued with either
standard or Ca2+-free buffer containing vehicle(s) (water, dimethyl sulfoxide, methanol,
ethanol, or chloroform, individually or in combination) or drug(s) of interest (individually or
in cassette) for 10 min at 37°C. The final concentration of each vehicle was ≤0.1% (v/v) of
the treatment solution. After removal of the buffer, hepatocytes were incubated for 10 min at
37°C with 1.5 ml of [3H]-taurocholate (1 µM), and vehicle(s) or drug(s) of interest in
standard buffer. Following this incubation, hepatocytes were rinsed three times with 2 ml
ice-cold standard buffer. Cells were lysed by the addition of 1 ml 0.5% (v/v) Triton X-100 in
phosphate-buffered saline to each well, and the plate was shaken for a minimum of 20 min
at room temperature.
Sample Analysis
Samples were analyzed by liquid scintillation spectroscopy using a Packard Tri-Carb
scintillation counter (PerkinElmer Life and Analytical Sciences). The protein concentrations
of SCH were determined in duplicate using BCA protein assay reagents and bovine serum
albumin as the reference standard (0.2 – 1 mg/ml), as instructed by the manufacturer.
Nonspecific binding of [3H]-taurocholate was determined in Matrigel™-overlaid BioCoat™
plates without hepatocytes. Data were corrected for nonspecific binding and normalized to
protein content.
Data Analysis
The biliary excretion index (BEI, representing the percent of accumulated compound that
resides in bile canaliculi) and the intrinsic in vitro biliary clearance (in vitro Clbiliary; ml/
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min/kg) of taurocholate were calculated using B-CLEAR® technology (Qualyst, Inc.,
Raleigh, NC; Liu et al., 1999a) and the following equations:
(1)
(2)
where substrate accumulation in cells+bile was determined in hepatocytes preincubated in
standard buffer, cellular accumulation of substrate was determined in hepatocytes
preincubated in Ca2+-free buffer, and AUCmedium was determined as the product of the
taurocholate concentration in medium and the incubation time. Because the taurocholate
medium concentration at the end of the incubation did not differ by more than 10% from the
concentration at the start of the incubation, the concentration of taurocholate in the medium
was defined as the initial concentration. Rat in vitro Clbiliary values were converted to ml/
min/kg based on 200 mg protein/g of liver and 40 g liver/kg of rat body weight (Seglen,
1976). Human in vitro Clbiliary values were converted to ml/min/kg based on 71 mg protein/
g of liver and 25.7 g liver/kg of human body weight (Davies and Morris, 1993).
Accumulation in cells+bile and cells, BEI, and in vitro Clbiliary results are reported as a
percentage of control data. An arbitrary cutoff was set at 80% of control to detect small
changes that may have occurred in taurocholate hepatobiliary disposition; any treatment that
produced a mean value at or below this cutoff was considered to have an inhibitory effect.
The clinical translation of this cutoff is unknown. This work serves as an initial
benchmarking exercise towards determining a future inhibition cutoff value that can be used
as a trigger to further assess the cholestatic potential of a drug.
Cytotoxicity Testing
To assess the toxicity of each treatment that inhibited bile acid transport, rat SCH were
incubated with 2 ml standard buffer or Ca2+-free buffer containing the drug(s) of interest for
10 min at 37°C. The buffer was removed, and the hepatocytes were incubated for an
additional 10 min at 37°C with 1.5 ml standard buffer containing the drug(s) of interest and
non-radiolabelled taurocholate (1 µM). The culture medium was collected and LDH leakage
was measured using the Cytotoxicity Detection Kit, according to the manufacturer’s
instructions. The degree of LDH release was expressed as a percentage of maximum cellular
LDH release, determined by incubation of rat SCH with 2% (v/v) Triton X-100.
(3)
The individual drugs and drug cassettes that caused a notable inhibition of taurocholate
accumulation, BEI, and in vitro Clbiliary in rat SCH were tested for toxicity: ampicillin;
nafcillin; rifampin; cyclosporin A; pioglitazone; troglitazone; troglitazone and rifampin;
troglitazone and ampicillin; troglitazone, phenytoin, pioglitazone, and cyclosporin A;
troglitazone, pioglitazone, and cyclosporin A; pioglitazone and troglitazone; cyclosporin A,
phenytoin, and troglitazone; cyclosporin A and troglitazone; troglitazone, phenobarbital, and
indomethacin; minocycline, cyclosporin A, and pioglitazone; oxacillin and troglitazone;
minocycline and troglitazone; and troglitazone and phenobarbital. Each drug was
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administered at the same concentration that was used in the prior experiments to determine
the effect on taurocholate hepatobiliary disposition (Table 1). None of the treatments were
toxic as measured by release of LDH into the culture medium (data not shown).
RESULTS
Hepatobiliary Disposition of Taurocholate in Rat and Human SCH
The accumulation in cells+bile, accumulation in cells, BEI, and in vitro Clbiliary of
taurocholate in untreated rat and human SCH is illustrated in Figure 2. Human SCH
accumulated taurocholate in cells to a greater extent than rat SCH; however, human SCH
appeared to have a lower BEI for taurocholate than rat SCH. The in vitro Clbiliary of
taurocholate was similar between rat and human SCH.
Modulation of Taurocholate Hepatobiliary Disposition in Rat SCH
Table 1 summarizes the effects of known and suspected hepatotoxic drugs from various
treatment classes on four measures of taurocholate hepatobiliary disposition in rat SCH:
taurocholate accumulation in cells+bile, accumulation of taurocholate in cells, BEI, and in
vitro Clbiliary. None of the vehicle controls had an effect on any of these disposition
parameters (data not shown). Of the 34 drugs tested, two altered all four measures (rifampin
and cyclosporin A), six altered three measures (ampicillin, nafcillin, piroxicam,
carbamazepine, pioglitazone, troglitazone), four altered two measures (carbenicillin,
cloxacillin, oxacillin, pentamidine), two altered one measure (ticarcillin, prednisone), and 20
had no notable effects (<20% change from control). Compared to control, rifampin and
cyclosporin A decreased taurocholate accumulation in cells+bile, BEI, and in vitro Clbiliary,
and increased cellular accumulation. Ampicillin, carbenicillin, cloxacillin, nafcillin,
oxacillin, carbamazepine, pioglitazone, and troglitazone decreased taurocholate
accumulation in cells+bile and in vitro Clbiliary with no notable change in BEI compared to
control, suggesting that uptake of taurocholate was mainly inhibited. In addition, many of
these drugs (ampicillin, nafcillin, carbamazepine, pioglitazone, and troglitazone) also
decreased cellular accumulation of taurocholate. Ticarcillin only decreased cellular
taurocholate accumulation. Conversely, pentamidine and piroxicam increased accumulation
of taurocholate in cells+bile and in vitro Clbiliary compared to control, while piroxicam also
increased cellular taurocholate accumulation. Prednisone increased only cellular
accumulation of taurocholate.
Cassette Dosing of Hepatotoxic Drugs in Rat SCH
The utility of the administration of drugs in cassette to determine the effects on taurocholate
hepatobiliary disposition in rat SCH was investigated. The effects of numerous cassettes on
the same four measures of taurocholate hepatobiliary disposition (accumulation in cells
+bile, accumulation in cells, BEI, and in vitro Clbiliary) were compared to the effects of an
anchor compound (a single compound utilized in each of the cassettes tested). The anchor
compounds were selected in order to provide a range of effects on taurocholate disposition
to which combinations of compounds could be compared for additive or synergistic effects.
Menadione-containing cassettes—Menadione served as a negative control because it
had no effect on taurocholate disposition on its own. When menadione was administered in
cassette with prednisone and bifonazole, there were no notable effects (<20% change from
control) on taurocholate accumulation in cells+bile (Figure 3A), BEI (Figure 3B), or on in
vitro Clbiliary (Figure 3B) compared to menadione alone. The increase in cellular
taurocholate accumulation in the menadione cassette containing prednisone was similar to
the effect caused by prednisone alone (27% increase compared to control; Table 1). No
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notable effects on the four measures of taurocholate hepatobiliary disposition were observed
with menadione, isoniazid, and clotrimazole in cassette (Figure 3A and 3B).
Phenobarbital-containing cassettes—Phenobarbital also served as a negative control.
Compared to control, phenobarbital and troglitazone in cassette decreased taurocholate
accumulation in cells+bile and cells (77% and 55%, respectively; Figure 4A), and in vitro
Clbiliary (80%; Figure 4B); there was no notable effect on the BEI of taurocholate (Figure
4B). These changes were similar to the effect caused by troglitazone alone. Likewise,
phenobarbital in cassette with troglitazone and indomethacin also decreased accumulation of
taurocholate in cells+bile and cells (76% and 62%, respectively; Figure 4A), and in vitro
Clbiliary (78%; Figure 4B), with no notable effect on BEI (Figure 4B). However, there was
no further change in any of the parameters compared to the phenobarbital and troglitazone
cassette, indicating that indomethacin does not alter taurocholate disposition, similar to what
was found when indomethacin was administered alone (Table 1). Overall, these results for
taurocholate hepatobiliary disposition when troglitazone was added to the cassette were
similar to the results observed when troglitazone, but not phenobarbital, was administered
alone (Table 1, Figures 4A and 4B).
Oxacillin-containing cassettes—Oxacillin affected two of the four parameters of
taurocholate disposition and was selected as an anchor compound to determine if additional
parameters would be affected when administered in cassette. Compared to control, treatment
with oxacillin and cloxacillin decreased the accumulation of taurocholate in cells+bile (30%)
and cells (30%; Figure 5A), and in vitro Clbiliary (30%; Figure 5B); there was no notable
change in BEI (Figure 5B). Oxacillin in cassette with cloxacillin and azlocillin had no
effects (Figure 5A and 5B). Treatment with oxacillin in cassette with cloxacillin and
ampicillin decreased the cellular accumulation of taurocholate (25%; Figure 5A). Oxacillin
and ampicillin in cassette did not affect any of the four measures of taurocholate
hepatobiliary disposition (Figure 5A and 5B), unlike the decrease in taurocholate
accumulation in cells+bile and cells, and in vitro Clbiliary ampicillin caused when
administered alone (Table 1). Taurocholate accumulation in cells+bile (31%; Figure 5A) and
in vitro Clbiliary (33%; Figure 5B) were decreased by treatment with the cassette containing
oxacillin, ampicillin, and cyclosporin A. Treatment with oxacillin, ampicillin, and nafcillin
decreased taurocholate accumulation in cells+bile (56%) and cells (47%; Figure 5A), and in
vitro Clbiliary (56%; Figure 5B), with no notable change in BEI (Figure 5B). These decreases
were slightly more compared to treatment with oxacillin and nafcillin (40%, 41%, and 40%,
respectively; Figures 5A and 5B). Treatment with oxacillin in cassette with ampicillin and
amoxicillin decreased taurocholate accumulation in cells+bile (29%) and cells (35%; Figure
5A), and in vitro Clbiliary (29%; Figure 5B); there was no notable change in BEI (Figure 5B).
In contrast, oxacillin and amoxicillin alone did not decrease any of the four measures of
taurocholate hepatobiliary disposition (Figures 5A and 5B). Treatment with oxacillin in
cassette with carbenicillin decreased the accumulation of taurocholate in cells+bile (24%)
and cells (40%; Figure 5A), and in vitro Clbiliary (22%; Figure 5B); there was no notable
change in BEI (Figure 5B). Oxacillin in cassette with azlocillin and ticarcillin decreased the
accumulation of taurocholate in cells+bile and cells (23% and 20%, respectively; Figure
5A), and in vitro Clbiliary (23%; Figure 5B), with no notable effect on BEI (Figure 5B).
Oxacillin in cassette with troglitazone decreased taurocholate accumulation in cells+bile and
cells (90% and 59%, respectively; Figure 5A), BEI (30%; Figure 5B), and in vitro Clbiliary
(93%; Figure 5B). In summary, the effects on the hepatobiliary disposition of taurocholate
that were observed with treatment of oxacillin-containing cassettes were similar to effects
produced by treatment with oxacillin alone (Table 1, Figures 5A and 5B) when variability
was taken into account. However, cassettes containing either nafcillin or troglitazone further
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decreased taurocholate accumulation in cells+bile and cells, BEI, and in vitro Clbiliary
compared to oxacillin alone (Table 1, Figures 5A and 5B).
Nafcillin-containing cassettes—Nafcillin affected three of the four parameters of
taurocholate disposition and was selected as an anchor compound to determine if the
parameters would be further affected when administered in combination. The five treatments
utilizing cassettes containing nafcillin decreased taurocholate accumulation in cells+bile and
cells (Figure 6A), and in vitro Clbiliary (Figure 6B) compared to control: nafcillin and
ticarcillin (31%, 21%, and 32%, respectively); nafcillin and cloxacillin (53%, 31%, and
55%, respectively); nafcillin and oxacillin (40%, 41%, and 40%, respectively; as noted
previously from Figure 5); nafcillin, oxacillin, and ampicillin (56%, 47%, and 56%,
respectively); and nafcillin and ampicillin (51%, 54%, and 51%, respectively). There were
no notable effects on BEI (Figure 6B). The effects produced by nafcillin-containing
cassettes on taurocholate hepatobiliary disposition were similar to those produced by
treatment with nafcillin alone (Table 1, Figures 6A and 6B).
Pioglitazone-containing cassettes—Pioglitazone also affected three out of the four
measures of taurocholate hepatobiliary disposition to a greater degree than nafcillin but to a
lesser extent than troglitazone. Compared to control, the five treatments utilizing
pioglitazone in cassette decreased taurocholate accumulation in cells+bile and cells (Figure
7A), and in vitro Clbiliary (Figure 7B): pioglitazone and cyclosporin A (61%, 48%, and 63%,
respectively); pioglitazone, cyclosporin A, and phenytoin (62%, 28%, and 65%,
respectively); pioglitazone, cyclosporin A, phenytoin, and troglitazone (90%, 57%, and
94%, respectively); pioglitazone and troglitazone (85%, 76%, and 86%, respectively); and
pioglitazone and ampicillin (68%, 60%, and 68%, respectively). The only cassette to
decrease the BEI of taurocholate contained pioglitazone, cyclosporin A, phenytoin, and
troglitazone (38%; Figure 7B). The effects produced by pioglitazone-containing cassettes
were similar to those produced by treatment with pioglitazone alone (Table 1, Figures 7A
and 7B), except there was a further decrease in taurocholate accumulation in cells+bile and
in vitro Clbiliary caused by the two pioglitazone cassettes containing troglitazone, and a
decrease in BEI caused by the cassette containing pioglitazone, cyclosporin A, phenytoin,
and troglitazone.
Troglitazone-containing cassettes—Troglitazone was one of three compounds
(troglitazone, cyclosporin A, rifampin) that had the greatest effects on taurocholate
disposition. Cassettes containing troglitazone and cyclosporin A decreased taurocholate
accumulation in cells+bile and cells (Figure 8A), BEI (Figure 8B), and in vitro Clbiliary
(Figure 8B) compared to control: troglitazone and cyclosporin A (91%, 67%, 27%, and
94%, respectively); troglitazone, cyclosporin A, and phenytoin (92%, 59%, 55%, and 97%,
respectively); and troglitazone, cyclosporin A, phenytoin, and pioglitazone (90%, 57%,
38%, and 94%, respectively; as noted previously from Figure 7). Troglitazone in cassette
with either oxacillin, rifampin, or with minocycline plus phenytoin also decreased
taurocholate accumulation in cells+bile (90%, 95%, and 91%, respectively) and cells (59%,
45%, and 58%, respectively; Figure 8A), BEI (30%, 100%, and 43%, respectively; Figure
8B), and in vitro Clbiliary (93%, 100%, and 95%, respectively; Figure 8B). Treatment with
troglitazone and minocycline in cassette decreased taurocholate accumulation in cells+bile
and cells (77% and 71%, respectively; Figure 8A), and in vitro Clbiliary (78%; Figure 8B);
this treatment caused no notable change in BEI (Figure 8B). As noted previously from
Figure 7, troglitazone and pioglitazone in cassette decreased taurocholate accumulation in
cells+bile and cells (85% and 76%, respectively; Figure 8A), and in vitro Clbiliary (86%;
Figure 8B) with no notable effect on BEI (Figure 8B). Treatment with troglitazone and
phenobarbital in cassette decreased taurocholate accumulation in cells+bile and cells (77%
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and 55%, respectively; Figure 8A), and in vitro Clbiliary (80%; Figure 8B), as noted
previously from Figure 4. Also noted previously from Figure 4, treatment with troglitazone,
phenobarbital, and indomethacin in cassette also decreased taurocholate accumulation in
cells+bile and cells (76% and 62%, respectively; Figure 8A), and in vitro Clbiliary (78%;
Figure 8B). Troglitazone in cassette with valproic acid and ibuprofen decreased the
accumulation of taurocholate in cells+bile and cells (85% and 68%, respectively; Figure
8A), and in vitro Clbiliary (87%; Figure 8B). Overall, the results of taurocholate
accumulation in cells+bile and cells, and in vitro Clbiliary are similar to those obtained when
troglitazone was administered alone (Table 1, Figures 8A and 8B).
Cyclosporin A-containing cassettes—Cyclosporin A affected all four measures of
taurocholate disposition and was selected as an anchor compound to determine if any
parameters would be further affected when administered in combination with other
compounds. Treatment with cyclosporin A in cassette with troglitazone decreased
taurocholate accumulation in cells+bile and cells (91% and 67%, respectively; Figure 9A),
BEI (27%; Figure 9B), and in vitro Clbiliary (94%; Figure 9B) compared to control, as noted
previously from Figure 8. Similar decreases in the four measures were observed when two
drugs were added to the cyclosporin A-troglitazone cassette (Figures 9A and 9B): phenytoin
(92%, 59%, 55%, and 97%, respectively), and phenytoin plus pioglitazone (90%, 57%, 38%,
and 94%, respectively). As noted previously from Figure 7, cyclosporin A in cassette with
pioglitazone alone decreased taurocholate accumulation in cells+bile and cells (61% and
48%, respectively; Figure 9A), and in vitro Clbiliary (63%; Figure 9B) with no notable
change in BEI (Figure 9B). Treatment with cyclosporin A, pioglitazone, and phenytoin in
cassette decreased the accumulation of taurocholate in cells+bile and cells (62% and 28%,
respectively; Figure 9A), and in vitro Clbiliary (65%; Figure 9B); there was no notable
change in BEI (Figure 9B). Cyclosporin A in cassette with phenytoin and minocycline
decreased taurocholate accumulation in cells+bile (25%; Figure 9A), BEI (27%; Figure 9B),
and in vitro Clbiliary (39%; Figure 9B), and increased cellular taurocholate accumulation
(64%; Figure 9A). Cyclosporin A in cassette with ampicillin only decreased in vitro Clbiliary
(20%; Figure 9B), while treatment with cyclosporin A in cassette with ampicillin and
oxacillin decreased taurocholate accumulation in cells+bile (31%; Figure 9A) and in vitro
Clbiliary (33%; Figure 9B), as noted previously from Figure 5. Cyclosporin A in cassette with
only amoxicillin decreased taurocholate accumulation in cells+bile (38%; Figure 9A) and in
vitro Clbiliary (44%; Figure 9B). Cassettes containing cyclosporin A and one of the
glitazones further decreased accumulation of taurocholate in cells+bile and cells, and in vitro
Clbiliary compared to cyclosporin A alone; the decrease was greater with troglitazone than
with pioglitazone (Table 1, Figures 9A and 9B).
Modulation of Taurocholate Hepatobiliary Disposition by Hepatotoxic Drugs in Human
SCH
The effects of hepatotoxic drugs, administered individually, on the hepatobiliary disposition
of taurocholate in human SCH are presented in Table 1. Compared to control, troglitazone
decreased taurocholate accumulation in cells+bile and cells, BEI, and in vitro Clbiliary.
Pioglitazone decreased taurocholate accumulation in cells+bile and cells, and in vitro
Clbiliary. Nafcillin only decreased cellular taurocholate accumulation, while cyclosporin A
only decreased taurocholate in vitro Clbiliary. Additionally, as seen in Figure 10, tienilic acid
decreased taurocholate accumulation in cells+bile and cells, and in vitro Clbiliary.
Figure 10 illustrates the effects of hepatotoxic drugs administered in cassette on taurocholate
hepatobiliary disposition in human SCH. Two drug cassettes, troglitazone combined with
tienilic acid, and cloxacillin combined with nafcillin, were studied. The troglitazone and
tienilic acid cassette decreased taurocholate accumulation in cells+bile (82%) and cells
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(68%), BEI (23%), and in vitro Clbiliary (86%) compared to control; these results were
similar to those following incubation with troglitazone alone (Table 1, Figure 10). The
cloxacillin and nafcillin cassette decreased cellular taurocholate accumulation (38%)
compared to control, similar to results following incubation with nafcillin alone (Table 1,
Figure 10).
DISCUSSION
Modulation of hepatobiliary transport proteins may be an important mechanism underlying
DILI. In humans and rodents, BSEP/Bsep and NTCP/Ntcp are largely responsible for
hepatic bile acid transport, and are subject to xenobiotic interactions and genetic mutations
(reviewed in Kosters and Karpen, 2008; Pauli-Magnus and Meier, 2006; Trauner and Boyer,
2003). Inhibition of BSEP/Bsep can decrease biliary excretion of bile acids, and the
detergent-like effects of accumulated bile acids can cause toxicity (reviewed in Sokol et al.,
2006). A number of drugs, including cyclosporin A, troglitazone, and bosentan, inhibit
BSEP/Bsep and also have been reported to cause clinical cases of cholestasis (reviewed in
Kosters and Karpen, 2008). A robust assay to identify potentially cholestatic compounds
early in drug development would be beneficial.
In vitro Clbiliary in SCH reflects both the uptake and efflux of a compound. The BEI
primarily reflects excretion of substrate across the canalicular domain. Pioglitazone,
troglitazone, ampicillin, carbenicillin, cloxacillin, nafcillin, oxacillin, and carbamazepine
inhibited the in vitro Clbiliary of taurocholate without affecting the BEI, suggesting that they
primarily inhibited the uptake of bile acids into rat SCH at the concentrations investigated
(Table 1). Inhibition of in vitro Clbiliary varied from ∼25% to 92%. Because taurocholate is
primarily transported by Ntcp (reviewed in Kosters and Karpen, 2008; Trauner and Boyer,
2003), these drugs most likely impair bile acid transport via Ntcp inhibition. Additional
studies are required to distinguish Ntcp inhibition from Oatp inhibition, similar to those
performed by Marion et al. (2007) in suspended hepatocytes utilizing Na+-containing and
Na+-free buffers to distinguish between Ntcp- and Oatp-mediated taurocholate uptake. The
key observation with these compounds was that the majority of bile acid inhibition was
associated with inhibition of hepatic uptake rather than canalicular efflux, which suggests
that increased plasma bile acid concentrations may be driven more likely by attenuation of
hepatic uptake than by Bsep inhibition. These compounds may inhibit Bsep at higher
concentrations than those used in this study; however, drug concentrations achieved within
hepatocytes are unknown. Furthermore, a metabolite of the compound may be a more potent
inhibitor of either bile acid uptake and/or excretion than the parent compound, as is the case
with troglitazone (Funk et al., 2001); the short incubation time used in this study may not
have been sufficient for appreciable metabolite formation.
Cyclosporin A and rifampin inhibited both the in vitro Clbiliary and BEI of taurocholate
(Table 1), indicating that both uptake of taurocholate into hepatocytes and subsequent
excretion into bile canaliculi were inhibited. Importantly, intracellular taurocholate
accumulation increased with both of these drugs, possibly due to greater inhibition of efflux.
This situation could potentially result in cholestasis with cellular damage which is, by
definition, mixed hepatic injury (Lucena et al., 2008).
The overall findings from administration of a single hepatotoxic drug to rat SCH are in
agreement with previous studies characterizing the inhibition of Ntcp and/or Bsep by some
of these compounds in different in vitro models. Troglitazone, used as a positive control in
our study, decreased taurocholate uptake in both canalicular and basolateral liver plasma
membranes (Snow and Moseley, 2007). Kemp et al. (2005) and Marion et al. (2007)
reported that troglitazone inhibited taurocholate accumulation in a dose-dependent manner
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with a marginal to no decrease in BEI in rat SCH. Using canalicular liver plasma
membranes, Stieger et al. (2000) reported that rifampin and cyclosporin A inhibited Bsep-
mediated taurocholate transport. In conventionally-cultured primary rat hepatocytes,
cyclosporin A competitively inhibited the uptake and efflux of taurocholate in a
concentration-dependent manner (Kukongviriyapan and Stacey, 1988). Fattinger et al.
(2000) reported that Na+-independent uptake of taurocholate via Oatps was inhibited by low
concentrations of rifampin, while higher concentrations also inhibited Na+-dependent uptake
via Ntcp in short-term conventional cultures of primary rat hepatocytes. Finally, Horikawa
et al. (2003) reported that high concentrations of cloxacillin, chlorpromazine, and colchicine
inhibited taurocholate uptake by rat canalicular liver plasma membranes via Bsep.
Colchicine reportedly causes cholestasis in rats (Crocenzi et al., 1997); therefore, colchicine
was expected to inhibit Bsep and decrease taurocholate efflux from hepatocytes into bile.
However, in the present study, colchicine did not alter any of the four measures of
taurocholate hepatobiliary disposition (Table 1). A longer incubation time with colchicine
may be necessary to impair taurocholate hepatobiliary disposition since the mechanism of
action of colchicine is to disrupt microtubule action and trafficking of Bsep to the
membrane. Piroxicam causes cholestatic jaundice in humans (Hepps et al., 1991),
suggesting impaired bile acid transport. In rat SCH, increased accumulation of taurocholate
in cells+bile and cells, and increased in vitro Clbiliary with no change in BEI supports
perturbation of bile acid transport in rats. This perturbation may be due to inhibition of bile
acid efflux by transport proteins located on the basolateral membrane.
Results following administration of hepatotoxic drugs in cassettes to rat SCH were similar to
those observed when hepatotoxic drugs were administered singly, suggesting that a single
potent inhibitor defined the inhibition profile. Drugs that did not inhibit the in vitro Clbiliary
of taurocholate alone showed no inhibition when administered in cassette; the same occurred
for the BEI of taurocholate. In general, drugs that inhibited the in vitro Clbiliary and/or BEI
when administered alone inhibited the corresponding parameter(s) when administered in
cassette. When multiple drugs that inhibited in vitro Clbiliary and/or BEI were administered
in cassette, increased inhibition of taurocholate transport usually resulted. However, the
increased inhibition was neither additive nor synergistic, except in the case of troglitazone
and rifampin administered in cassette (Figure 8). One possible reason for this is that the
drugs administered in cassette may all preferentially inhibit Oatps rather than Ntcp or vice
versa. Further studies are required to define the specific mechanism(s) of inhibition. Overall,
however, these results indicate that the cassette dosing approach with rat SCH is a useful
model system to study the ability of a compound to inhibit bile acid transport.
Lastly, the utility of cassette dosing in human SCH was investigated. Pioglitazone,
troglitazone, and tienilic acid inhibited taurocholate cellular accumulation and in vitro
Clbiliary, while troglitazone also decreased the BEI. These compounds may primarily inhibit
bile acid uptake into hepatocytes, although troglitazone additionally inhibits the canalicular
efflux of taurocholate. Results observed after 5 µM troglitazone administration are in good
accordance with previously published data (Marion et al., 2007) in which troglitazone
decreased cellular taurocholate accumulation and BEI in a dose-dependent manner in human
SCH. In contrast to results herein, Kostrubsky et al. (2003) reported that both 1 and 10 µM
cyclosporin A inhibited taurocholate uptake and canalicular efflux in human SCH in a dose-
dependent manner following a 15-min preload and a 10-min efflux with taurocholate and
cyclosporin A. Horikawa et al. (2003) reported that cloxacillin (75 µM) and cyclosporin A
(1 µM) inhibited taurocholate uptake by human canalicular liver plasma membranes,
indicating inhibition of taurocholate canalicular efflux by BSEP. However, consistent with
our findings of decreased in vitro Clbiliary, Mita et al. (2006) demonstrated that inhibition of
NTCP rather than BSEP was more important in the inhibition of bile acid transport by
cyclosporin A in NTCP- and BSEP-expressing LLC-PK1 cells. Some of the differences
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observed in these studies may be due to differential expression and/or activity of NTCP and/
or BSEP between hepatocytes from different donors; other differences may be dependent on
the concentration of drug or the in vitro model.
When comparing the results between rat and human SCH treated with the same compound, a
few similarities and differences were observed (Table 1). Minocycline had no effect on
taurocholate hepatobiliary disposition in either rat or human SCH, while pioglitazone
appeared to primarily inhibit taurocholate uptake into both rat and human SCH at the
concentrations tested. In contrast, cloxacillin, nafcillin, and oxacillin inhibited taurocholate
uptake into rat SCH but had no effect in human SCH. Cyclosporin A prominently inhibited
the uptake and biliary efflux of taurocholate in rat SCH, with a modest decrease in
taurocholate biliary clearance at the concentration examined (3 µM) in human SCH.
Troglitazone, on the other hand, appeared to only inhibit taurocholate uptake in rat SCH, but
inhibited both taurocholate uptake and biliary efflux in human SCH at the concentration
tested. The differences observed in taurocholate hepatobiliary disposition between rat and
human SCH may be due to differences in the sensitivity of transport proteins (i.e. Ntcp/
NTCP, Oatps/OATPs, Bsep/BSEP) to inhibition caused by the individual drugs, as
previously reported for Ntcp/NTCP inhibition. Leslie et al. (2007) found Ntcp to be more
sensitive to inhibition by bosentan than NTCP. Marion et al. (2007) reported that NTCP is
more sensitive to inhibition by troglitazone than Ntcp, and McRae et al. (2006) found the
same to be true for ritonavir, saquinivir, and efavirenz. These findings emphasize the
differences between species in hepatic transport protein function. In addition, there could
also be differences in the sensitivity of a transport protein to inhibition between humans
because of polymorphisms.
The cutoff set at 80% of control was selected arbitrarily to detect small changes in
taurocholate hepatobiliary disposition. However, changes in biliary disposition of this
magnitude may not result in clinically-detectable cholestasis. A higher threshold (i.e., >20%
change from control) may be more relevant and would take into account polymorphisms that
occur in transport proteins, which may render a certain population more susceptible to
perturbation of bile acid transport. A cutoff set at 50% would exclude many compounds,
including some β-lactam antibiotics that have been reported to cause rare cases of
cholestasis in humans. Using the 80% cutoff, results from this study suggest that inhibition
of bile acid transport was not a function of drug class, except for the glitazones and some
penicillin analogs.
In summary, the present work demonstrates the utility of a novel in vitro approach, rat and
human SCH in combination with cassette dosing, to increase throughput when screening
compounds (i.e., potential drug candidates) for inhibition of bile acid transport. Compounds
should first be screened in combination, and then follow-up studies of the cassettes causing
inhibition would be required to identify which individual component(s) caused inhibition.
These subsequent single-agent studies also would minimize false positives. False negatives
could be minimized by utilizing a compound in multiple combinations and at more than one
concentration. Furthermore, exposure of rat and human SCH to compounds for an adequate
period of time to allow formation of metabolites prior to assessing taurocholate transport
could provide additional information about whether the metabolite(s) and/or the unchanged
drug is responsible for inhibition of bile acid transport. Overall, results indicate that the
majority of hepatotoxic drugs do not inhibit bile acid transport at clinically relevant
concentrations. For those drugs that did affect bile acid transport in vitro, the majority
appear to decrease only the in vitro Clbiliary, reflecting an inhibition of bile acid uptake from
the medium into hepatocytes as opposed to an inhibition of bile acid efflux from hepatocytes
into bile canaliculi. The drugs that only inhibit bile acid uptake may cause hepatotoxicity by
another mechanism and/or cause toxicity elsewhere in the body due to increased plasma
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levels of bile acids. In contrast, the few drugs that altered taurocholate hepatobiliary
disposition to the greatest extent (i.e., troglitazone and rifampin) were those which have
been associated with the most reports of clinical hepatotoxicity. Thus, this approach is useful
in detecting compounds that inhibit the hepatic uptake and/or excretion of bile acids, and
which may cause cholestasis or hepatotoxicity.
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Figure 1. Schematic depicting method of calculating taurocholate accumulation in hepatocytes
and bile canaliculi in SCH
SCH were preincubated in HBSS+Ca2+ buffer (standard buffer), or HBSS-Ca2+ buffer
(Ca2+-free buffer) to disrupt tight junctions sealing the bile canalicular space (Liu et al.,
1999b). Subsequently, cultures were rinsed and SCH were incubated in standard buffer with
substrate for 10 min. In SCH preincubated with standard buffer, [3H]taurocholate (circles)
was taken up into SCH and excreted into the bile canaliculi; substrate accumulation (cells
+bile) was determined at 10 min. In adjacent wells where SCH were preincubated with
HBSS-Ca2+ buffer to open tight junctions, [3H]taurocholate excreted into the bile
compartment was released into the medium; substrate accumulation (cells) was determined
at 10 min. The mass of [3H]taurocholate excreted into the bile during the 10-min incubation
was estimated as the difference in accumulation in SCH with intact and disrupted tight
junctions [(cells+bile) minus cells].
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Figure 2. Hepatobiliary disposition of taurocholate in vitro
Rat and human SCH were incubated with [3H]-taurocholate (1 µM) for 10 min following
incubation in either standard or Ca2+-free buffer. Solid bars represent accumulation in
hepatocytes and bile canaliculi (cells+bile). Open bars represent accumulation in
hepatocytes (cells). BEI and in vitro Clbiliary were calculated as described in Materials and
Methods. Data are presented as mean ± SD for n=9 livers in triplicate for rat SCH, and mean
± ½ of the range for n=2 livers in triplicate for human SCH.
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Figure 3. Effect of menadione-containing cassettes on the hepatobiliary disposition of
taurocholate in rat SCH
Rat SCH were incubated with menadione (MEN) alone or in cassette with prednisone (PDS)
and bifonazole (BIF), or isoniazid (INH) and clotrimazole (CLT), in either standard or Ca2+-
free buffer for 10 min, followed by an additional 10-min incubation with [3H]-taurocholate
(1 µM) and the drug(s) of interest. (A) Taurocholate accumulation. Solid bars represent
accumulation in hepatocytes and bile canaliculi (cells+bile). Open bars represent
accumulation in hepatocytes (cells). (B) BEI and in vitro Clbiliary were calculated as
described in Materials and Methods. Data are presented as mean ± ½ of the range for n=2
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livers in duplicate. Data for treatment with menadione alone also were presented in Table 3
and serve as a reference in this figure.
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Figure 4. Effect of phenobarbital-containing cassettes on the hepatobiliary disposition of
taurocholate in rat SCH
Rat SCH were incubated with phenobarbital (PB) alone or in cassette with troglitazone
(TRO) with or without indomethacin (IND) in either standard or Ca2+-free buffer for 10
min, followed by an additional 10-min incubation with [3H]-taurocholate (1 µM) and the
drug(s) of interest. (A) Taurocholate accumulation. Solid bars represent accumulation in
hepatocytes and bile canaliculi (cells+bile). Open bars represent accumulation in
hepatocytes (cells). (B) BEI and in vitro Clbiliary were calculated as described in Materials
and Methods. Data are presented as mean ± ½ of the range for n=2 livers in duplicate. Data
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for treatment with phenobarbital alone also were presented in Table 3 and serve as a
reference in this figure.
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Figure 5. Effect of oxacillin-containing cassettes on the hepatobiliary disposition of taurocholate
in rat SCH
Rat SCH were incubated with oxacillin (OXA) alone or in cassette with cloxacillin (CLX),
azlocillin (AZL), ampicillin (AMP), cyclosporin A (CSA), nafcillin (NFC), carbenicillin
(CAR), amoxicillin (AMO), ticarcillin (TIC), and/or troglitazone (TRO) in either standard or
Ca2+-free buffer for 10 min, followed by an additional 10-min incubation with [3H]-
taurocholate (1 µM) and the drug(s) of interest. (A) Taurocholate accumulation. Solid bars
represent accumulation in hepatocytes and bile canaliculi (cells+bile). Open bars represent
accumulation in hepatocytes (cells). (B) BEI and in vitro Clbiliary were calculated as
described in Materials and Methods. Data are presented as mean ± ½ of the range for n=2
livers in duplicate. Data for treatment with oxacillin alone also were presented in Table 3
and serve as a reference in this figure.
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Figure 6. Effect of nafcillin-containing cassettes on the hepatobiliary disposition of taurocholate
in rat SCH
Rat SCH were incubated with nafcillin (NFC) alone or in cassette with ticarcillin (TIC),
cloxacillin (CLX), oxacillin (OXA), and/or ampicillin (AMP) in either standard or Ca2+-free
buffer for 10 min, followed by an additional 10-min incubation with [3H]-taurocholate (1
µM) and the drug(s) of interest. (A) Taurocholate accumulation. Solid bars represent
accumulation in hepatocytes and bile canaliculi (cells+bile). Open bars represent
accumulation in hepatocytes (cells). (B) BEI and in vitro Clbiliary were calculated as
described in Materials and Methods. Data are presented as mean ± ½ of the range for n=2
livers in duplicate. Data for treatment with nafcillin alone also were presented in Table 3 and
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serve as a reference in this figure. Data for treatment of nafcillin in cassette with oxacillin
with or without ampicillin also were presented in Figure 4 for comparison to treatment with
oxacillin alone.
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Figure 7. Effect of pioglitazone-containing cassettes on the hepatobiliary disposition of
taurocholate in rat SCH
Rat SCH were incubated with pioglitazone (PIO) alone or in cassette with cyclosporin A
(CSA), phenytoin (PHN), troglitazone (TRO), and/or ampicillin (AMP) in either standard or
Ca2+-free buffer for 10 min, followed by an additional 10-min incubation with [3H]-
taurocholate (1 µM) and the drug(s) of interest. (A) Taurocholate accumulation. Solid bars
represent accumulation in hepatocytes and bile canaliculi (cells+bile). Open bars represent
accumulation in hepatocytes (cells). (B) BEI and in vitro Clbiliary were calculated as
described in Materials and Methods. Data are presented as mean ± ½ of the range for n=2
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livers in duplicate. Data for treatment with pioglitazone alone also were presented in Table 3
and serve as a reference in this figure.
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Figure 8. Effect of troglitazone-containing cassettes on the hepatobiliary disposition of
taurocholate in rat SCH
Rat SCH were incubated with troglitazone (TRO) alone or in cassette with cyclosporin A
(CSA), phenytoin (PHN), pioglitazone (PIO), minocycline (MCL), oxacillin (OXA),
rifampin (RIF), valproic acid (VPA), ibuprofen (IBU), phenobarbital (PB), and/or
indomethacin (IND) in either standard or Ca2+-free buffer for 10 min, followed by an
additional 10-min incubation with [3H]-taurocholate (1 µM) and the drug(s) of interest. (A)
Taurocholate accumulation. Solid bars represent accumulation in hepatocytes and bile
canaliculi (cells+bile). Open bars represent accumulation in hepatocytes (cells). (B) BEI and
in vitro Clbiliary were calculated as described in Materials and Methods. Data are presented
as mean ± ½ of the range for n=2 livers in duplicate, except for troglitazone (mean ± SD for
n=3 livers in duplicate). Data for treatment with troglitazone alone also were presented in
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Table 3 and serve as a reference in this figure. Data for treatment of troglitazone in cassette
with phenobarbital with or without indomethacin also were presented in Figure 3 for
comparison to treatment with phenobarbital alone. Data for treatment of troglitazone in
cassette with oxacillin also were presented in Figure 4 for comparison to treatment with
oxacillin alone. Data for treatment of troglitazone in cassette with cyclosporin A, phenytoin,
and/or pioglitazone also were presented in Figure 6 for comparison to treatment with
pioglitazone alone.
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Figure 9. Effect of cyclosporin A-containing cassettes on the hepatobiliary disposition of
taurocholate in rat SCH
Rat SCH were incubated with cyclosporin A (CSA) alone or in cassette with pioglitazone
(PIO), phenytoin (PHN), troglitazone (TRO), minocycline (MCL), ampicillin (AMP),
oxacillin (OXA), and/or amoxicillin (AMO) in either standard or Ca2+-free buffer for 10
min, followed by an additional 10-min incubation with [3H]-taurocholate (1 µM) and the
drug(s) of interest. (A) Taurocholate accumulation. Solid bars represent accumulation in
hepatocytes and bile canaliculi (cells+bile). Open bars represent accumulation in
hepatocytes (cells). (B) BEI and in vitro Clbiliary were calculated as described in Materials
and Methods. Data are presented as mean ± ½ of the range for n=2 livers in duplicate,
except for cyclosporin A (mean ± SD for n=3 livers in duplicate). Data for treatment with
cyclosporin A alone also were presented in Table 3 and serve as a reference in this figure.
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Data for treatment of cyclosporin A in cassette with oxacillin and ampicillin also were
presented in Figure 4 for comparison to treatment with oxacillin alone. Data for treatment of
cyclosporin A in cassette with pioglitazone, phenytoin, and/or troglitazone also were
presented in Figure 6 and Figure 7 for comparison to treatment with pioglitazone or
troglitazone alone, respectively.
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Figure 10. Effect of hepatotoxic compounds on the hepatobiliary disposition of taurocholate in
human SCH
Human SCH were incubated with [3H]-taurocholate and the hepatotoxic compound(s) of
interest for 10 min following a 10-min incubation in standard or Ca2+-free buffer containing
the same hepatotoxic compound(s). (A) Taurocholate accumulation. Solid bars represent
accumulation in hepatocytes and bile canaliculi (cells+bile). Open bars represent
accumulation in hepatocytes (cells). (B) BEI and in vitro Clbiliary were calculated as
described in Materials and Methods. Data are presented as the mean for n=1 liver in
duplicate, except for troglitazone and cloxacillin (mean ± ½ of the range for n=2 livers in
duplicate). TRO, troglitazone; TA, tienilic acid (3.00 µM); CLX, cloxacillin; NFC, nafcillin.
Data for treatment with troglitazone, cloxacillin, and nafcillin alone also were presented in
Table 3 and serve as a reference in this figure.
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